Related Experiment Video
Updated: Sep 25, 2026
Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
Published on: August 4, 2021
Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer
Solveig Schulz1, Johannes Schmitt, Wolfgang Weise
1Department of Obstetrics and Gynecology, Otto-von-Guericke-University, Magdeburg, Germany. Solveig.Schulz@Medizin.Uni-Madgeburg.de
Objective:
A variety of human cancers has been shown to express somatostatin receptors which can be utilized for in vivo tumor targeting. Although the somatostatin receptor status of mammary and ovarian cancer has been studied in detail, somatostatin receptors have not been examined in other gynecological malignancies such as cervical or endometrial carcinoma.
Methods:
We have previously developed a panel of somatostatin receptor subtype-specific antibodies that effectively stain formalin-fixed, paraffin-embedded human tumor tissue. In the present study, we have used these antibodies to determine the somatostatin receptor status of 21 randomly selected cervical carcinomas and 28 randomly selected endometrial carcinomas.
Results:
In cervical carcinoma, the incidence of somatostatin receptor expression was sst2A (12/21, approximately 57%) > sst3 (9/21, approximately 43%) > sst1 (8/21, approximately 38%) > sst4 (0/21, 0%) = sst5 (0/21, 0%). In endometrial carcinoma, the incidence of somatostatin receptor expression was sst3 (12/28, approximately 43%) > sst2A (11/28, approximately 39%) > sst1 (9/28, approximately 32%) > sst4 (1/28, approximately 4%) = sst5 (1/28, approximately 4%). Somatostatin receptor-like immunoreactivity was in most cases located at the plasma membrane and completely blocked with antigenic peptide. The expression of somatostatin receptor subtypes was independent of patient age, diagnosis, tumor stage, and histological grade.
Conclusion:
Our findings reveal a previously unappreciated high incidence of sst1, sst2A, and sst3 somatostatin receptors in human cervical and endometrial cancers and suggest that a subgroup of receptor-positive uterine carcinomas may be a potential target for diagnostic and therapeutic intervention with stable somatostatin analogs.
Insights
This study found a high incidence of somatostatin receptors (sst1, sst2A, sst3) in cervical and endometrial cancers. These findings suggest potential diagnostic and therapeutic applications for uterine carcinomas using somatostatin analogs.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Somatostatin receptors are expressed in various human cancers, enabling in vivo tumor targeting.
- While studied in mammary and ovarian cancers, their status in cervical and endometrial carcinomas remains largely unexamined.
Purpose of the Study:
- To investigate the expression of somatostatin receptor subtypes in cervical and endometrial carcinomas.
- To assess the potential of these receptors for targeted diagnostic and therapeutic interventions in gynecological malignancies.
Main Methods:
- Utilized a panel of somatostatin receptor subtype-specific antibodies for immunohistochemical staining.
- Analyzed 21 cervical and 28 endometrial carcinomas using formalin-fixed, paraffin-embedded tissue.
Main Results:
- Somatostatin receptor subtype 2A (sst2A) was expressed in approximately 57% of cervical cancers, followed by sst3 (43%) and sst1 (38%).
- In endometrial cancers, sst3 was most frequent (43%), followed by sst2A (39%) and sst1 (32%).
- Receptor expression was independent of patient age, diagnosis, tumor stage, and histological grade.
Conclusions:
- A significant incidence of sst1, sst2A, and sst3 somatostatin receptors was identified in cervical and endometrial cancers.
- Receptor-positive uterine carcinomas represent a potential target for diagnostic and therapeutic strategies involving somatostatin analogs.
